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Introduction
According to many authors, the hemostatic system in
the fetus has unique features. The distinctions do not
only concern differences in the concentrations of hemo-
static components, but also in the ability to generate
and inhibit thrombin, as compared to adults. Two diag-
nostic methods that have been developed in the last two
decades allow further growth of knowledge on fetal
hemostasis, particularly on the coagulation and fibri-
nolytic systems. Thus, sampling the cord blood during
pregnancy (cordocentesis) enables investigation of the
fetal coagulation system throughout intrauterine life
and due to the micromethods, even tiny samples can be
used for testing. In Poland, T. Wyrzykiewicz and M.
Kurzawa developed their own micromethods for
neonatological purposes as early as in 1981 [1]).
The new methodological possibilities coincided
with a negative assessment of then-current analyses of
hemostasis in the fetus and infant. In 1991, the Sub-
committee on Neonatal Hemostasis of the Scientific
and Standardization Committee (abbreviation of the
earlier name: ICTH) informed that the analyses carried
out until then had had numerous methodological errors
(heterogeneity of the material and methods, other inad-
vertences) and therefore had to be considered not fully
reliable [2].
The well known components of hemostasis include
(i) the coagulation and fibrinolysis systems, (ii) blood
platelets, and (iii) vascular endothelium. The forma-
tion of a hemostatic plug occurs due to interactions
between these components. Procoagulants and antico-
agulants contribute to the generation of thrombin, the
key coagulation enzyme.
The aim of the following article is to provide a sur-
vey of the literature concerning procoagulants and
anticoagulants in the blood of the fetus, particularly
changes in their concentration during pregnancy, to
present selected referential values that have been
established in the last decade and to discuss some
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Abstract: In intrauterine life, hemostasis is maintained by the same components as in extrauterine life (blood platelets,
coagulation and fibrinolysis systems, involvement of the vascular wall); in the fetus, however, these components show sig-
nificant differences of a quantitative/qualitative nature. In the present study, we surveyed the literature on the coagulation
system in the fetus. We focused on the velocity of development of the coagulation system, being reflected in the increased
concentration of all procoagulants and anticoagulants (a rise from approximately 20% in the middle of pregnancy to about
60% or more in the period of labor; exceptions: factors V,VIII and XIII which in the labor period reach the adult level) and
screening test results (prothrombin time, aPTT - activated prothrombin time, and thrombin time). Reference values were
given for the 19-38 weeks of pregnancy and the labor term. Biochemical features of fetal fibrinogen and PIVKA factors
were also discussed. The role of activated protein C (APC) in the maintenance of balance between procoagulants and anti-
coagulants was postulated as well as the role of APC in the formation of thrombin activatable fibrinolysis inhibitor (TAFI).
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Definition and a list of procoagulants and
anticoagulants
The term procoagulants pertains to all coagulation fac-
tors (procoagulants sensu stricto) marked with Roman
numerals (I-III, V, VII-XIII) and two coagulation fac-
tors without such numerals (prekallikrein and high
molecular weight kininogen - HMWK). It is also used
with reference to phospholipids as an indispensable
component of the coagulation process (involved in the
formation of two types of the tenase complex - VIIIa-
IXa-X+phospholipid; TF-VIIa-X+phospholipid, and
the prothrombinase complex: Va-Xa-II+phospholipid).
The coagulation factors include a group of the con-
tact phase factors (factors XI,XII, kallikrein and
HMWK), a group of vitamin K-dependent procoagu-
lants (factors II, VII, IX and X) and a group consisting
of fibrinogen, factor V, factor VIII, and factor XIII;
tissue factor (TF) (factor III, earlier called tissue
thromboplastine) is not considered as belonging to any
of these groups. TF and contact phase factors are
responsible for the initiation of coagulation (or more
precisely for the initiation of thrombin generation),
called TF-dependent or TF-independent coagulation
(contact phase coagulation), respectively. 
For decades, the interaction of the coagulation fac-
tors was presented as the cascade system. The classic
cascade schema was later supplemented with informa-
tion about the role of these factors in complexes (two
tenase complexes and a prothrombin complex (Fig.1).
The above mentioned interaction results in the genera-
tion of thrombin, the coagulation enzyme that can
transform fibrinogen into fibrin, activate blood
platelets, participate in the formation of antithrombo-
genic APC (Activated Protein C) and Thrombin Acti-
vatable Fibrinolysis Inhibitor (TAFI) (Fig. 2).
The term anticoagulants is assigned to proteins
inhibiting thrombin generation or inactivating the
already generated thrombin (Fig. 3). The mechanism
of action is a criterion for the distinction between indi-
rect and direct anticoagulants:
(a). Indirect anticoagulants include tissue factor
pathway inhibitor, TFPI, and activated protein C
(APC), the last being transformed by thrombin/ throm-
bomodulin complex from inactive protein C to serine
enzyme APC with participation of protein S, PS, as a
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Fig. 1. Basic mechanism of coagulation cascade: action of the
tenase and prothrombinase complexes and thrombin formation.
Abbreviations:  TF – tissue factor, HMK – high molecular weight
kininogen.
Fig. 2. Protein C pathway: generation of activated protein C (APC)
under the effect of the trombin/thrombomodulin complex; activity
of APC: (a) inactivation of Va and VIII a factors, (b) generation of
TAFI (thrombin activatable fibrinolysis inhibitor).
Fig. 3. A fragment of the coagulation cascade illustrating the for-
mation of three markers of thrombin generation: thrombin-
antithrombin complexes (TAT), prothrombin fragments 1+2
(F1+2) and fibrinopeptides A (FpA).
cofactor. Both anticoagulants suppress thrombin gen-
eration - TFPI by forming a quaternary
TF/VIIa/TFPI/Xa complex, whereas APC by inactivat-
ing Va and VIIIa factors;
(b). Direct anticoagulants include antithrombin III
(AT III) and heparin cofactor II (HC II); they inactivate
the existing thrombin to form stable complexes. The
thrombin-antithrombin III complexes (TAT) are useful
for clinical purposes as markers of thrombin.
Concentrations of procoagulants and antico-
agulants in fetal blood
Basic information on hemostasis in the fetus and infant
is included in publications by Andrew M. et al. [3,4],
Reverdiau-Moalic P. et al. [5] and Kuhle S. et al. [6]. 
The hemostatic proteins in fetal blood are synthe-
sized by the fetus itself as they do not cross the pla-
cental barrier from the mother.
The synthesis of fibrinogen - factor I - begins dur-
ing the 6th week of intrauterine life, i.e. the embryo
period (the time from the zygote stage to the 8th week
of pregnancy). The fetal blood starts to coagulate
around the 11th week of intrauterine life (after Kuhle et
al. [6]), which means that at that time all the factors
indispensable for thrombin generation as well as the
coagulation protein fibrinogen are already present in
the blood. It is difficult, however, to precisely deter-
mine the time at which particular coagulation factors
or fibrinolysis components appear for the first time in
the blood. All authors agree that around the 34th week
(30th to 38th week) of pregnancy the concentration of
the coagulation factors rapidly increases. Delivery is
probably an additional accelerating impulse, which,
however, has not been satisfactorily documented yet.
The most important data from the clinical point of
view are presented in Table 1 (procoagulants), Table 2
(anticoagulants) and Table 3 (selected tests). The cited
authors have formulated the following conclusions:
• The earlier is the pregnancy age of the fetus, the
lower the concentration of procoagulants and anti-
coagulants; thus, in fetuses at around 20 weeks of
age, the concentrations of the respective procoagu-
lants and anticoagulants are most often below 20%
of the values for adults.
• A significant increase in the concentration of the
procoagulants occurs in the period of the 30th - 38th
week of pregnancy, although only three factors - V,
VII and XIII - reach the level of adults at delivery
time.
• An increase is also noted in the level of anticoagu-
lants, but only antithrombin (earlier called
antithrombin III) and heparin cofactor II reach
about 60% of the adult value at the time of delivery,
while the concentration of other anticoagulants is
around 50%. The levels corresponding to adult val-
ues are reached about the 6th month of life [3],
though that of protein C - as late as in teenagers
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Table 1. The levels of coagulation factors in cord blood (normal values). Ranges are given only for values that are most important for
clinicians; more detailed data can be found in the publications cited [3-6]. The percentage values have been taken from literature or cal-
culated based on this literature [3-6].
• Delivery accelerates an increase in the level of pro-
coagulants and anticoagulants, which can be
observed after delivery [7].
• vWF has not been analyzed with the fetus yet,
though in infants the concentration is low in com-
parison with adults [8].
Are there fetal forms of the coagulation
factors?
Most probably all fetal procoagulants and anticoagu-
lants show certain structural and functional differences
as compared to adults. It can be expected that the fetal
features are most pronounced in the early period of
development. The most frequently mentioned is fetal
fibrinogen, whereas PIVKA-type factors (Protein
Induced in Vitamin K-Absence) and other coagulation
proteins seem to be seldom reported. It is known that
structural defects result in divergence between meas-
urements of antigen and activity (higher immunologi-
cal than functional value). This proves poorer hemo-
static utility of the fetal factors. 
Fetal fibrinogen increases the content of sialic acid
and reduces susceptibility to thrombin as compared to
adults. PIVKAs, i.e. vitamin K-dependent coagulation
factors, are deprived of COOH groups in the so called
gamma position, thus being unable to form complexes
with calcium and phospholipids during thrombin gener-
ation. The effect of PIVKA on fetal hemostasis has not
been investigated by the authors cited above [3,4,5,6].
However, fetal hemostasis in the newborn has been the
subject of congress discussion (Haemostasis 1986;16:
suppl 5, p. 85-86 ). Most likely, PIVKA factors have not
been searched for in the fetal blood yet. 
In adult humans, PIVKA factors are known to orig-
inate as a result of high deficiency of vitamin K, e.g.
when cumarine or phenyloindandione derivatives are
administered. PIVKA factors are detected in the blood
of healthy newborns, mainly as PIVKA-II (nearly in
50% of the examined). It is not clear whether PIVKA
production is caused by vitamin K deficiency only or
by liver immaturity? Nevertheless, administration of
vitamin K is recommended in the prophylactic treat-
ment of perinatal bleeding in women undergoing
antiepileptic therapy [9]. 
Thrombin generation in fetal blood
Thrombin generation in the fetus has been studied
using standard screening tests (activated partial throm-
boplastin time - aPTT, and prothrombin time ) [4] and
by measurements of prothrombin fragments F 1+2
[10]. The ability of the fetus to form thrombin is found
to be from 1/3 to 1/2 of that of adult. The immediate
cause of the lowered thrombin generation in the fetus
is claimed to a low concentration of contact factors and
vitamin K-dependent factors. The most important
cause is said to be a low prothrombin level (prothrom-
548 M. Uszyñski et al.
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2009:47(4): 548 (545-550) 
10.2478/v10042-009-0094-4
Table 2. The levels of anticoagulants in cord blood. Ranges are not given for all the values (the Reader is referred to the original manu-
script [5]). The percentage values have been taken from literature or calculated based on the literature data [3-6]; *[21].
Table 3. Cord blood - normal screening test results [5].
bin deficit). When the deficiency was supplemented to
the adult level, the activity of the generated thrombin
was similar to that of adults [4].Thrombin generation
in fetal blood occurs with low concentrations of anti-
coagulants, which according to some authors allows
sufficient production of thrombin [10].
Inactivation of thrombin in fetus blood
Many authors have investigated anticoagulant syner-
gism in the newborn and infant but not in the fetus. It
has been demonstrated, among others, that tissue fac-
tor pathway inhibitor (TFPI) and antithrombin (AT)
amplify the anticoagulant action of activated protein C
(APC) [11]. According to clinicians, the anticoagulant
effect obtained by means of recombinant human APC
is greater in adults than in children, which can be
explained by the fact that the levels of TFPI and AT are
higher in adults than in children [12].
Each of the anticoagulants shows a specific effect:
(i) TFPI regulates the coagulation by forming a qua-
ternary TF/VIIa/TFPI/Xa complex, inhibiting pro-
thrombinase formation; (ii) APC inactivates Va and
VIIIa factors; (iii) AT inactivates the already generated
thrombin to form inactive complexes (thrombin/
antithrombin complexes, TAT). 
There are two forms of PS in the plasma: (i) free
and functionally active form which can participate in
the protein C pathway, and (ii) PS complexed with
C4b-binding protein being functionally inactive. The
anticoagulant activity of PS becomes higher when the
free fraction of PS increases [12,13,14].
Low stability of hemostasis in fetuses and
infants
Despite low ability of thrombin generation in healthy
fetuses and infants, their hemostasis is efficient, which
surprises researchers and clinicians. On the other hand,
however, surprising is the passage from the norm
(homeostasis) to complications (undercoagulability
and bleedings or disseminated intravascular coagula-
tion, DIC). This is discussed in terms of shallow hemo-
static equilibrium in fetuses and infants, and explained
enigmatically as being a feature of immature hemosta-
tic systems in fetuses and infants (a), a result of low
levels of procoagulants in the blood (b) or due to other
causes (c) [3,5,6,8,15].
Activated protein C resistance (APCr) in cord
blood
Resistance to active protein C is a known risk factor of
thromboembolic complications in newborns, infants
and adults [16]. APCr is in 90% caused by V Leiden
factor - a genetic defect affecting approximately 5% of
the general population [17]. There is also APCr asso-
ciated with the use of contraceptives and pregnancy
(elevated levels of factor VIII, fibrinogen and von
Willebrand factor in a pregnant woman being non-
genetic causes of APCr) [18]. 
It can be assumed that the Leiden-type factor is
present in fetuses as frequently as in adults, although
no research has been conducted to confirm the
assumption. Some authors hold that nonspecific APCr
can occur also in fetuses and infants, but others have
not supported this claim [literature survey according to
[19]). 
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